-
Jun 21, 2024 | 
onclive.com | Ibrahim Aldoss |Elias Jabbour
Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic LeukemiaIbrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.
-
Jun 21, 2024 | 
onclive.com | Ibrahim Aldoss |Elias Jabbour
The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALLIbrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
-
Jun 21, 2024 | 
onclive.com | Ibrahim Aldoss |Elias Jabbour
Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALLIbrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
-
Jun 21, 2024 | 
onclive.com | Ibrahim Aldoss |Elias Jabbour
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
-
Jun 14, 2024 | 
onclive.com | Ibrahim Aldoss
CommentaryVideoJune 14, 2024Author(s):Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.
-
May 6, 2024 | 
onclive.com | Ibrahim Aldoss
May 6, 2024Ibrahim Aldoss, MD, discusses the utility of ponatinib in the phase 3 PhALLCON trial for patients with newly diagnosed, Ph+ acute lymphoblastic leukemia.
-
Apr 29, 2024 | 
onclive.com | Ibrahim Aldoss
Ibrahim Aldoss, MD, hematologist-oncologist, associate professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope; member, the Gehr Family Center for Leukemia Research, codirector, the Hematology Tissue Bank, City of Hope and the Leukemia Registry, discusses the mechanism of action of ponatinib (Iclusig) and highlights the phase 3 PhALLCON trial (NCT03589326) in patients with newly diagnosed, Philadelphia chromosome (Ph)–positive acute...
-
Jan 26, 2024 | 
onclive.com | Ibrahim Aldoss
January 26, 2024Ibrahim T. Aldoss, MD, discusses the use of revumenib monotherapy in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements. Ibrahim T.
-
Aug 29, 2023 | 
cco.amegroups.org | Vaibhav Agrawal |Ibrahim Aldoss
Have a website account?Log In orRegister for exclusive website content. Home / Vol 12, No 4 (August 31, 2023) / Searching for the optimal sequence of dual-targeted CAR T cells in relapsed/refractory acute lymphoblastic leukemia PDF 262 views Full Text 2 views COI Form
-
Jul 12, 2023 | 
nature.com | Ibrahim Aldoss |Yan Wang |Xiuli Wang |Mary Clark
Dear Editor,CD19-targeted chimeric antigen receptor (CAR) T cell therapy induces remission in the majority of patients with relapsed and refractory (r/r) B-cell acute lymphoblastic leukemia (ALL), including those who have exhausted all other available salvage therapies [1,2,3].
